Effects of metformin on the uterus of d‐galactose‐induced aging mice: Histomorphometric, immunohistochemical localization (B‐cell lymphoma 2, Bcl2‐associated X protein, and active capase3), and oxidative stress study

Abstract d ‐galactose (DG)‐induced rodent aging model has widely been used for the study of age‐related dysfunctions of various organs, including gonads and uterus. Antidiabetic drug metformin has gained an attention as antiaging drug in model organism and human but its effect on uterus has not been studied in relation to induced aging. Therefore, we investigated the effect of metformin on uterus of DG‐induced aging mice model. Mice were randomly divided into three groups, that is, control (CN), DG‐induced aging model and aging model treated with metformin. Histomorphometric results showed significantly decreased number of uterine glands, endometrial thickness, and increased luminal epithelium height in aging model. Furthermore, metformin resumed the number of uterine glands, endometrial thickness, and luminal epithelium height up to CN group. Metformin has also significantly decreased the age‐associated oxidative stress (malondialdehyde and lipid hydroperoxide). Superoxide dismutase was significantly decreased in both treated groups compared to the CN group. However, catalase and glutathione peroxidase enzymes were significantly increased by metformin compared to the aging model. Immunostaining of active caspase3 and BAX were intense in the endometrium of aging model compare to CN‐ and metformin‐treated groups. Localization of B‐cell lymphoma 2 (Bcl2) showed intense immunostaining in the uterus of CN‐ and metformin‐treated groups, with mild immunostaining in aging model. Our observations suggested that metformin treatment might be helpful for management of age‐associated uterine dysfunctions. Moreover, it may be concluded that metformin might ameliorate uterine dysfunctions by reducing oxidative stress, suppressing apoptosis, and increasing the survival/antiapoptotic protein Bcl2.